Analytical Quality By Design Using Design Of Experiments

Source: Catalent

By L. Xin, J. Crichton, S. Beard, W. Hong, Y. Chen, T. Stone, and Y. Li

lab flask science 450x300

Quality by Design (QbD) has been established as a guideline for pharmaceutical product development. The primary objective of analytical process development is to provide an optimized analytical method ready for method validation. This includes set points of operating parameters, ranges of these parameters, and system suitability targets (SST) criteria, Design of Experiment (DoE) is the centerpiece of analytical QbD. Using DoE, assay development begins with the creation of an analytical target profile to define method objectives including critical method attributes (e.g., range, accuracy, precision, ruggedness, and robustness) and key method attributes (e.g., data turnaround and assay transferability). It is common for contract manufacturing and development organizations to receive analytical methods at different stages of development. A different DoE approach can be used for assays that differ in level of readiness for our assay development pipeline (Figure 1). Here we present our DoE assay development pipeline. This pipeline approach delivers optimized, robust, and rugged analytical methods that are ready for method qualification.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online